Showing all 4 results

  • Placeholder
    In Stock

    Amiodarone Injection

    Free

    Product Composition & Strength

    We supply this product as a Sterile Solution in Amber Glass Ampoules. The formulation utilizes specific co-solvents to solubilize the lipophilic Amiodarone molecule.

    Active IngredientStrength (Standard)Therapeutic Role
    Amiodarone HCl BP/USP150 mg / 3 ml (50 mg/ml)Antiarrhythmic Agent
    Vehicle / SolventsQ.S.Polysorbate 80 / Benzyl AlcoholSolubilizing Agents

    *Pack Sizes: Tray of 5 Ampoules or 10 Ampoules.

  • Amiodarone-Tablets-BP-200-mg
    Amiodarone-Hydrochloride-Tablets
    In Stock

    Amiodarone Tablet

    Free

    Product Composition & Available Strengths

    We manufacture Amiodarone in standard, internationally recognized strengths to allow for the intensive loading phase and lower maintenance doses required in cardiology.

    Active IngredientStandard StrengthsPrimary Clinical Target
    Amiodarone HCl BP / IP / USP100 mgLow-Dose Maintenance: For fine-tuned long-term rhythm control and geriatric titration.
    Amiodarone HCl BP / IP / USP200 mgStandard Therapy: Used for initial institutional oral loading phases and standard daily maintenance.
  • Placeholder
    In Stock

    Lidocaine Injection

    Free

    Product Composition & Strength

    We supply this product as a Sterile Solution in Glass Ampoules or Multi-dose Vials.

    Active IngredientStrengthCommon Application
    Lidocaine Hydrochloride1% (10 mg/ml)Infiltration / Minor Suturing / Diagnostic Blocks
    Lidocaine Hydrochloride2% (20 mg/ml)Major Nerve Blocks / Epidural / Anti-arrhythmic
    ExcipientsSodium Chloride / Methylparaben (in vials)Isotonicity / Preservative

    *Available in preservative-free (PF) versions for spinal/epidural use.

  • Placeholder
    In Stock

    Lignocaine Injection

    Free

    Lignocaine injection (also known as Lidocaine) is a sterile, aqueous solution primarily used as a local anaesthetic and antiarrhythmic agent. Its composition varies depending on whether it is a single-dose or multi-dose formulation and whether it includes a vasoconstrictor.